



02045356

SECURITIES AND EXCHANGE COMMISSION JUL 3 - 2002

Washington, D.C. 20549

1086

RECD S.E.C.

FORM 6-K

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the period ended July 2, 2002

PROCESSED

JUL 17 2002

THOMSON
FINANCIAL

Elan Corporation, plc

(Translation of registrant's name into English)

Lincoln House, Lincoln Place, Dublin 2, Ireland

(Address of principal executive offices)

Indicate by check mark whether the registrant files
or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒

Form 40-F ☐

Indicate by check mark whether the registrant by fur-
nishing the information contained in this Form is also thereby
furnishing the information to the Commission pursuant to
Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐

No ☒

CRGH

Elan ::::Corporate Bulletin::::

FOR IMMEDIATE RELEASE

Contacts:

Investors: (U.S.)

Jack Howarth

Ph: 212-407-5740

917-593-0036

800-252-3526

Investors: (Europe)

Emer Reynolds

Ph: 353-1-709-4000

00800 28352600

ELAN TO HOST CONFERENCE CALL

DUBLIN, IRELAND, July 2, 2002 -- Elan Corporation, plc (NYSE: ELN) ("Elan") announced that it will host a conference call at 8.30am EST on Tuesday, July 9 to discuss Elan's recently filed 2001 Annual Report on Form 20-F and the outlook for 2002. Exact call-in details will be made available shortly.

Live audio of the conference call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public. The conference call is expected to last one hour.

This event can be accessed through Elan's website, www.elan.com, and clicking on the Investor Relations section, then on the event icon. The event will be archived and available for replay for 48 hours after the event.

The 2001 Annual Report on Form 20-F was filed yesterday with the United States Securities and Exchange Commission ("SEC") and has been posted on the Investor Relations section of the Elan web site. The "Frequently Asked Questions" has also been updated and is available on the Elan web site, including a section on the 2001 Annual Report on Form 20-F. It is expected that there may be many people accessing Elan's web site for this information. For that reason, Elan requests your patience.

About Elan

Elan is a leading worldwide, fully integrated biopharmaceutical company headquartered in Ireland, with its principal facilities located in Ireland and the U.S. Elan is focused on the discovery, development, manufacturing, selling and marketing of novel therapeutic products in neurology, pain management and autoimmune diseases and the development and commercialisation of products using its extensive range of proprietary drug delivery technologies. Elan shares trade on the New York, London and Dublin Stock Exchanges.

This document and the attachments contain forward-looking statements about Elan's financial results and estimates, business prospects and products under development that involve substantial risks and uncertainties. You can identify these statements by the fact that they use words such as "anticipate", "estimate", "project", "envisage", "intend", "plan", "believe" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Among the factors that could cause actual results to differ materially from those described herein are the following: the success of research and development activities and the speed with which regulatory authorisations and product launches may be achieved; competitive developments affecting Elan's current products; the ability to successfully market both new and existing products domestically and internationally; difficulties or delays in manufacturing; the ability to meet generic and branded competition after the expiration of Elan's patents; trends towards managed care and health care cost containment; possible legislation affecting pharmaceutical pricing; exposure to product liability and other types of lawsuits; Elan's ability to protect its intellectual property both domestically and internationally; interest rate and foreign currency exchange rate fluctuations; governmental laws and regulations affecting domestic and foreign operations, including tax obligations; general changes in US and Irish generally accepted accounting principles; growth in costs and expenses; changes in product mix; the outcome of the ongoing SEC investigation and shareholder litigation, and the impact of acquisitions, divestitures, restructurings, product withdrawals and other unusual items. A further list and description of these risks, uncertainties and other matters can be found in Elan's Annual Report on Form 20-F for the fiscal year ended December 31, 2000, and in its Reports of Foreign Issuer on Form 6-K. Elan assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ELAN CORPORATION, plc

By: _____

William F. Daniel
Company Secretary

Date: July 3, 2002